CLINICAL TRIALS PROFILE FOR NERAMEXANE

Clinical Trials for Neramexane

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00090116 ↗	The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease	Completed	Forest Laboratories	Phase 3	Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).
NCT00405886 ↗	Neramexane for Tinnitus	Completed	Merz Pharmaceuticals GmbH	Phase 2	Tinnitus is commonly referred to as "ringing of the ears" - the perception of sounds in the absence of an external source of acoustic signals. Tinnitus may represent a severe disease and symptoms include depression, sleeping difficulties, decreased sound tolerance and hearing loss. One hypothesis is that tinnitus is caused by an increased activity of NMDA glutamate and dysfunctional alpha9/alpha10 acetylcholine receptors in the inner ear and central nervous system. Neramexane may alleviate tinnitus symptoms due to its NMDA and alpha9/alpha10 nACh receptor blocking activity. The purpose of this study is to assess the safety and efficacy of Neramexane compared with placebo in patients with subjective tinnitus.
NCT00661440 ↗	Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus	Completed	Merz Pharmaceuticals GmbH	Phase 2	The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only.
NCT00712283 ↗	Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers	Completed	Merz Pharmaceuticals GmbH	Phase 1	Determination of the ability to drive and operate machines after single and multiple oral dose of Neramexane as compared to placebo
NCT00739635 ↗	Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus	Completed	Merz Pharmaceuticals GmbH	Phase 3	The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
NCT00772980 ↗	Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus	Completed	Merz Pharmaceuticals GmbH	Phase 3	The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.

Clinical Trial Conditions for Neramexane

Condition Name

Condition Name for
Intervention	Trials
Healthy	5
Subjective Tinnitus	4
Healthy Subjects	2
Nystagmus, Acquired	2

Condition MeSH

Condition MeSH for
Intervention	Trials
Tinnitus	5
Nystagmus, Congenital	2
Nystagmus, Pathologic	2
Alzheimer Disease	1

Clinical Trial Locations for Neramexane

Trials by Country

Trials by Country for
Location	Trials
United States	51
Germany	11
Netherlands	8
Spain	5
Austria	4

Trials by US State

Trials by US State for
Location	Trials
California	4
New Jersey	3
Kentucky	3
Florida	3
Colorado	3

Clinical Trial Progress for Neramexane

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	3
Phase 1	8

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	14
Terminated	2

Clinical Trial Sponsors for Neramexane

Sponsor Name

Sponsor Name for
Sponsor	Trials
Merz Pharmaceuticals GmbH	15
Forest Laboratories	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	16